Effectiveness of tralokinumab for upadacitinib-refractory atopic dermatitis: 48-week retrospective study

J Am Acad Dermatol. 2025 Nov;93(5):1332-1334. doi: 10.1016/j.jaad.2025.07.040. Epub 2025 Jul 19.

Authors

Teppei Hagino¹, Hidehisa Saeki², Eita Fujimoto³, Naoko Kanda⁴

Affiliations

¹ Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Electronic address: teppei-hagino@nms.ac.jp.
² Department of Dermatology, Nippon Medical School, Tokyo, Japan.
³ Fujimoto Dermatology Clinic, Funabashi, Japan.
⁴ Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.

PMID: 40692046
DOI: 10.1016/j.jaad.2025.07.040

No abstract available

Keywords: atopic dermatitis; biologic; interleukin-13; tralokinumab; upadacitinib.